• Buccal administration
  • No first pass-hepatic degradation
  • Passage through the BBB
  • No exposure to plasmatic and interstitial degradation enzymes
  • Increased benefit/risk ratio
  • Superior pharmacokinetic profile with increased efficacy coupled with better tolerability
  • Low COGs through simple but patented manufacturing process
  • Finished product stable for 6 months at 40°C, and 3 years at room temperature for empty formulation
  • Suitable for pediatric use

AONYS® Technology offers major benefits. Active agents are administered through a non-invasive administration (mouth deposit). At the same time, it allows drugs to reach their intracellular targets, in the brain for example, while reducing the required dose and diminishing side effects.

Share:Share on Facebook